12th International Lung Cancer Congress (LCC)

Venue: Park Hyatt Aviara

Location: Carlsbad, California, United States

Event Date/Time: Jul 21, 2011 End Date/Time: Jul 24, 2011
Registration Date: Jul 21, 2011
Early Registration Date: Jul 20, 2011
Abstract Submission Date: Jun 02, 2011
Report as Spam


The 12th International Lung Cancer Congress is designed to provide participants with an update on advances in lung cancer research and therapy, including biology, pathology, screening, staging, personalized therapy, maintenance therapy, novel agents, and ongoing research in Cooperative Groups. Bringing key data from international oncology conferences to participants, the congress will emphasize the importance of personalized therapy and address other current topics of interest. State-of-the-art treatment for early-stage locally advanced and metastatic lung cancer will be discussed. In addition to non–small-cell lung cancer (NSCLC), the congress will address therapy for small-cell lung cancer (SCLC) and mesothelioma. A regular feature of the International Lung Cancer Congress is an update of research efforts from major Cooperative Groups from the United States, Europe, and Asia. The format of the meeting will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, question-and-answer sessions, and afternoon translational workshops focusing on future strategies in development for the treatment of lung cancer.

Target Audience
This educational activity is directed toward medical, surgical, and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to attend.

Learning Objectives
At the conclusion of this congress, you should be able to:

Evaluate the role of CT screening for early detection of lung cancer
Discuss the role of pulmonologists in the diagnosis of and treatment selection for patients with lung cancer
Appraise clinical data on adjuvant chemotherapy in patients with early-stage NSCLC
Evaluate the efficacy and toxicity of combined modality regimens in locally advanced NSCLC
Optimize therapy for patients with metastatic NSCLC based on biomarker status and tumor characteristics
Discuss the clinical benefits of maintenance therapy in advanced NSCLC
Personalize therapeutic approaches for patients with mesothelioma
Describe current approaches to patients with limited- and extensive-disease SCLC
Discuss clinical data on new targeted agents in development for lung cancer
Summarize current research activity in lung cancer from national and regional Cooperative Groups


7100 Four Seasons Point
United States